Kishan P V1, Uday Kumar C1, Shobha J C2, Usharani P3, Chandrasekhar E4. 1. DM Residents, Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical Sciences , Panjagutta, Hyderabad, India . 2. Professor & HOD, Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical Sciences , Panjagutta, Hyderabad, India . 3. Additional Professor, Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical Sciences , Panjagutta, Hyderabad, India . 4. Lab Analyst, Clinical Pharmacology & Medical Research Laboratory, Nizam's Institute of Medical Sciences , Panjagutta, Hyderabad, India .
Abstract
INTRODUCTION: Coronary heart disease is one of the most common cardiac health problem in India. Anti-platelet therapy is the cornerstone in the management of coronary heart disease. The current study was undertaken to compare the effect of different oral anti-platelet regimens on percentage inhibition of platelet aggregation in coronary heart disease patients using chronolog light transmittance aggregometry. MATERIAL AND METHODS: Blood samples of 215 consecutive patients diagnosed of coronary heart disease (Male: Female ratio- 142: 73) with mean age of 55.2 ±10.3 years, who underwent platelet aggregation test were analysed. Patients were either on aspirin, clopidogrel, prasugrel, cilostazol or a combination of these drugs in different dosages. Of the 215 coronary heart disease patients, 35, 115 and 65 patients were on single, dual and triple anti-platelet drug regimen respectively. RESULTS: The Percentage Inhibition of Platelet Aggregation (%IPA) in patients on dual anti-platelet regimen was highest i.e., 65.14 ± 23.23 as compared to 48.89 ± 22.16 in patients on monotherapy and 62.14 ± 21.64 in patients on triple anti-platelet regimen. Percentage of responders (> 40% inhibition of platelet aggregation) were 54.28%, 73.91% and 64.61% in single, dual and triple drug regimens respectively. Among responders on dual anti-platelet regimen, 64.7% were on aspirin + prasugrel and 35.3% were on aspirin + clopidogrel. The Percentage Inhibition of platelet aggregation in diabetics on dual anti-platelet regimen was 71.69 ± 17.54 as compared to 56.14 ± 23.29 in diabetics on triple anti-platelet regimen. CONCLUSION: Dual anti-platelet therapy containing prasugrel was found to be more effective than dual anti-platelet therapy containing clopidogrel on background aspirin therapy and triple anti-platelet therapy in terms of percentage inhibition of platelet aggregation in coronary heart disease patients especially those with concomitant diabetes, however this conclusion needs to be further confirmed by large-scale randomized clinical trials.
INTRODUCTION:Coronary heart disease is one of the most common cardiac health problem in India. Anti-platelet therapy is the cornerstone in the management of coronary heart disease. The current study was undertaken to compare the effect of different oral anti-platelet regimens on percentage inhibition of platelet aggregation in coronary heart diseasepatients using chronolog light transmittance aggregometry. MATERIAL AND METHODS: Blood samples of 215 consecutive patients diagnosed of coronary heart disease (Male: Female ratio- 142: 73) with mean age of 55.2 ±10.3 years, who underwent platelet aggregation test were analysed. Patients were either on aspirin, clopidogrel, prasugrel, cilostazol or a combination of these drugs in different dosages. Of the 215 coronary heart diseasepatients, 35, 115 and 65 patients were on single, dual and triple anti-platelet drug regimen respectively. RESULTS: The Percentage Inhibition of Platelet Aggregation (%IPA) in patients on dual anti-platelet regimen was highest i.e., 65.14 ± 23.23 as compared to 48.89 ± 22.16 in patients on monotherapy and 62.14 ± 21.64 in patients on triple anti-platelet regimen. Percentage of responders (> 40% inhibition of platelet aggregation) were 54.28%, 73.91% and 64.61% in single, dual and triple drug regimens respectively. Among responders on dual anti-platelet regimen, 64.7% were on aspirin + prasugrel and 35.3% were on aspirin + clopidogrel. The Percentage Inhibition of platelet aggregation in diabetics on dual anti-platelet regimen was 71.69 ± 17.54 as compared to 56.14 ± 23.29 in diabetics on triple anti-platelet regimen. CONCLUSION: Dual anti-platelet therapy containing prasugrel was found to be more effective than dual anti-platelet therapy containing clopidogrel on background aspirin therapy and triple anti-platelet therapy in terms of percentage inhibition of platelet aggregation in coronary heart diseasepatients especially those with concomitant diabetes, however this conclusion needs to be further confirmed by large-scale randomized clinical trials.
Authors: Per Olav Vandvik; A Michael Lincoff; Joel M Gore; David D Gutterman; Frank A Sonnenberg; Pablo Alonso-Coello; Elie A Akl; Maarten G Lansberg; Gordon H Guyatt; Frederick A Spencer Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Dominick J Angiolillo; Steven B Shoemaker; Bhaloo Desai; Hang Yuan; Ronald K Charlton; Esther Bernardo; Martin M Zenni; Luis A Guzman; Theodore A Bass; Marco A Costa Journal: Circulation Date: 2007-01-29 Impact factor: 29.690
Authors: Martin Ungerer; Kai Rosport; Andreas Bültmann; Richard Piechatzek; Kerstin Uhland; Peter Schlieper; Meinrad Gawaz; Götz Münch Journal: Circulation Date: 2011-04-18 Impact factor: 29.690
Authors: Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman Journal: Circulation Date: 2008-08-31 Impact factor: 29.690
Authors: Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol Journal: J Am Coll Cardiol Date: 2003-03-19 Impact factor: 24.094